← Oncology Approval Tracker

FDA DECISION ·

Inluriyo + Verzenio

imlunestrant with abemaciclib · Eli Lilly

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced or metastatic ER-positive, HER2-negative breast cancer with an ESR1 mutation identified by an FDA-authorized test, after progression on at least one endocrine therapy line.

LAMPGEN ANALYSIS

Why it matters

This combines an oral estrogen receptor antagonist with a CDK4/6 inhibitor in ESR1-mutated disease after endocrine progression. The prior-progression requirement distinguishes this decision from mutation-triggered switching before progression.

What research teams should watch

Capture the ESR1 test result, endocrine progression date and treatment history. The companion diagnostic and regimen-specific safety checks belong in the same handoff.

PRIMARY RECORDS

Sources